role of interleukin-13 on skeletal muscle glucose metabolism in type 2 diabetic patients involves microRNA let-7. Am J Physiol Endocrinol Metab 305: E1359 -E1366, 2013. First published October 8, 2013 doi:10.1152/ajpendo.00236.2013.-Low-grade inflammation associated with type 2 diabetes (T2DM) is postulated to exacerbate insulin resistance. We report that serum levels, as well as IL-13 secreted from cultured skeletal muscle, are reduced in T2DM vs. normal glucosetolerant (NGT) subjects. IL-13 exposure increases skeletal muscle glucose uptake, oxidation, and glycogen synthesis via an Aktdependent mechanism. Expression of microRNA let-7a and let-7d, which are direct translational repressors of the IL-13 gene, was increased in skeletal muscle from T2DM patients. Overexpression of let-7a and let-7d in cultured myotubes reduced IL-13 secretion. Furthermore, basal glycogen synthesis was reduced in cultured myotubes exposed to an IL-13-neutralizing antibody. Thus, IL-13 is synthesized and released by skeletal muscle through a mechanism involving let-7, and this effect is attenuated in skeletal muscle from insulin-resistant T2DM patients. In conclusion, IL-13 plays an autocrine role in skeletal muscle to increase glucose uptake and metabolism, suggesting a role in glucose homeostasis in metabolic disease.
THE ROLE OF SKELETAL MUSCLE-DERIVED FACTORS or "myokines" as signaling molecules and the link to metabolic homeostasis are not completely described. The most extensively studied myokines include interleukin (IL)-6, IL-8, and monocyte chemoattractant protein-1, which exert biological effects on glucose and lipid metabolism via autocrine, paracrine, and endocrine mechanisms (11, 34) . However, the role of IL-13 in the development of insulin resistance and type 2 diabetes mellitus (T2DM) is unclear.
IL-13 is secreted by activated Th2 cells and classified as an anti-inflammatory cytokine due to its ability to suppress the secretion of several macrophage and monocyte-derived inflammatory cytokines (6, 7) . Hence, IL-13 counteracts several cytokines linked to the development of insulin resistance in T2DM (27, 45) . IL-13 is a major mediator of airway hyperresponsiveness and mucus hypersecretion, two fundamental responses in the clinical manifestation of asthma (20) . IL-13-deficient mice display an impaired antigen-specific immunoglobulin G response but are otherwise viable with no reported disturbances in appearance or behavior (29) . Thus, IL-13 displays disparate biological functions, ultimately promoting either anti-inflammatory or pathological responses, the latter primarily in lung. Of metabolic relevance is that IL-13 is required for alternative activation towards the anti-inflammatory M2 macrophage phenotype in adipose tissue, resulting in enhanced insulin sensitivity in mice fed a high-fat diet (22) . Recent evidence implicates a role for IL-13 in controlling hepatic glucose production (41) .
There is a growing appreciation for the role of microRNAs (miRNAs) in regulation of gene expression (16) . miRNAs are implicated in several muscle-specific processes, such as myocyte proliferation and differentiation (8) , hypertrophy and atrophy (2, 28) , and aging-associated loss of muscle mass (9) . However, the link between miRNA and inflammatory factors in skeletal muscle function during the development of T2DM is elusive.
In the present study, we provide evidence that IL-13 has an autocrine effect on glucose metabolism in skeletal muscle. In cultured myotubes derived from T2DM patients, IL-13 secretion is reduced. We couple the regulation of IL-13 secretion to a mechanism dependent upon miRNA let-7. These findings implicate a previously unrecognized role for let-7 and IL-13 in the metabolic impairments characteristic of T2DM patients.
EXPERIMENTAL PROCEDURES
Human subjects. Studies were performed with approval from the local ethics committee and in accordance with the Declaration of Helsinki. Informed written consent was obtained from all participants before testing was initiated. Biopsies were obtained from the vastus lateralis portion of the quadriceps femoris muscle from 14 healthy people with normal glucose tolerance (NGT; 13 males, 1 female aged 62 Ϯ 1 yr; BMI 28.1 Ϯ 0.6 kg/m Ϫ2 and fasting blood glucose of 5.3 Ϯ 0.1 mM) and 11 T2DM patients (11 males aged 60 Ϯ 1 yr; BMI 28.8 Ϯ 1.0 kg/m Ϫ2 and fasting blood glucose of 7.9 Ϯ 0.3 mM) Table 1 shows characteristics of subjects included in serum analysis. Baseline characteristics of the young healthy controls in Fig. 4 have been described previously (12) .
Cell culture. Isolation of muscle satellite cells and myotube differentiation was performed as described (1) . Subcutaneous human adipose tissue was obtained from healthy volunteers from the paraumbilical region by needle aspiration under local anesthesia. Fat cells were prepared and isolated as described (38) .
Western blot analysis. Skeletal muscle cells were grown and differentiated into myotubes. Cells were serum starved for 4 h before exposure to insulin or IL-13 as indicated. Wortmannin (1 uM) was added 30 min before addition of either insulin or IL-13 for 30 min. Muscle cells were harvested, and protein concentration was determined using the BCA method (Pierce). Aliquots of lysates were solubilized in Laemmli buffer and separated by SDS-PAGE. Proteins were visualized by chemiluminescence and quantified by densitometry. Western blot analysis was performed using phosphospecific antibodies against Akt (Ser 473 ), signal transducer and activator of transcription 6 (STAT6; Tyr 641 ), glycogen synthase kinase-␣ and -␤ (GSK3-␣/␤; Ser 21/9 ), and antibodies against total abundance of Akt and STAT6 (Cell Signaling Technology). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Santa Cruz Biotechnology) was used to ensure equal protein loading.
Lipid oxidation. Lipid oxidation in response to IL-13 (1 ng/ml) in skeletal muscle cells was assessed by exposing myotubes to [ 3 H]palmitic acid and measuring the production of 3 H-labeled water as described (39) .
Glucose uptake and incorporation to glycogen. Myotubes were preincubated with or without IL-13 (1 ng/ml) for 2 h at 37°C and then stimulated with or without insulin (120 nM) for 30 min. Glucose uptake in skeletal muscle cells was performed as described (1) . Glucose uptake and lipolysis (glycerol release) in human adipocytes was performed as described (26) . Glycogen synthesis was determined by assessing the conversion of labeled glucose into glycogen as described (1) .
Glucose oxidation. Skeletal muscle cells were serum starved for 2 h and then preincubated with or without IL-13 (1 or 10 ng/ml) for 2 h at 37°C. Cells were then incubated with D-[U-
14 C]glucose (1 Ci/ml; final specific activity 0.18 Ci/mol) for 4 h at 37°C. The produced 14 C-labeled CO2 was released from the cell culture medium by adding 2 M HCl, which was then captured in small cups containing 2 M NaOH that were placed in each well. The radioactivity was determined by liquid scintillation counting (WinSpectral 1414 Liquid Scintillation Counter; Wallac). Total protein concentration was assessed and used for normalization. Each experiment was performed on triplicate wells.
Lactate production. Skeletal muscle cells were incubated with or without IL-13 (1 ng/ml) and insulin (120 nM) in serum-free DMEM. Cell media were collected in duplicate, and lactate concentration was determined as described (1) using a lactate kit (A-108; Biochemical Research Service Center).
ELISA. IL-13 and IL-4 secretion from the skeletal muscle cultures and serum was measured using commercial kits according to manufacturers' protocols (Invitrogen and Linco). Total protein concentration was assessed and used for normalization of IL-13 and IL-4 myotube secretion.
Quantitative real-time PCR analysis. Total RNA was prepared with the RNeasy Midi Kit (Qiagen) and then reverse-transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Reagents for real-time PCR analysis, primers (Assays-onDemand), and TaqMan Gene Expression Master Mix were from Applied Biosystems and used according to the manufacturer's protocol. GAPDH and ␤ 2-microglobulin were used as reference genes for normalization. Expression changes were evaluated according to the comparative C T method. For miRNA expression analysis, total RNA was isolated from skeletal muscle tissue (10 mg) or myotubes using TRIzol reagent (Invitrogen). Relative miRNA abundance of let-7a and let-7d was determined using target-specific reverse transcription and PCR primers and probes (Taqman MicroRNA Assays and TaqMan Universal PCR Master Mix; Applied Biosystems). SNORD44 abundance (Applied Biosystems) was stable across conditions and used as a housekeeping RNA, to which target miRNA expression was normalized. The average CT values of the unknown samples were converted to relative expression data using a standard curve generated from serial dilutions of pooled RNA. Gene and miRNA expression of specific products was amplified and detected with the ABI Prism 7000HT Sequence Detection System (Applied Biosystems) using default cycle parameters. Total RNA concentration and purity were verified spectrophotometrically using NanoDrop ND-1000 (ThermoFisher Scientific). All samples were analyzed in duplicate or triplicate.
miRNA transfection. Human myoblasts (8 ϫ 10 4 ) were seeded in a six-well format 36 h before transfection and grown (20% FBS in F-12 MEM) to 90% confluence. Transfection complexes for the let-7d mimic (Ambion) were formed using PrimeFect siRNA (Lonza, Denmark) in reduced serum medium (OptiMEM; Invitrogen). Cells were transfected (5 h) on day 0 and returned to differentiation medium (2% FBS in DMEM). A second transfection was performed 48 h after the first transfection. Culture medium was collected on day 4 of differentiation (48 h after the 2nd transfection) for IL-13 quantification. Control cells were transfected with a scrambled miRNA sequence (Ambion). Each experiment was performed on triplicate wells.
Statistics. Comparisons between two groups were performed using two-tailed paired or unpaired Student's t-test. ANOVA followed by Tukey's post hoc test was used for comparisons between three or more groups. Values not normally distributed as determined by the D'Agostino and Pearson omnibus normality test were log transformed prior to regression analysis. Statistically significant differences were defined as P Ͻ 0.05.
RESULTS
Reduced IL-13 level in conditioned media from cultured myotubes, as well in serum, from T2DM patients. The concentration of IL-13 was determined in media from cultured primary human skeletal muscle cells obtained from people with NGT or T2DM. IL-13 secretion from myotubes derived from T2DM patients was reduced by 75% compared with NGT subjects (Fig. 1A) . In contrast, the secretion of the IL-13-related cytokine IL-4 did not differ between the two groups (Fig. 1B) . mRNA expression of IL-13 ( Fig. 1C ) and the IL-13 receptor (IL-13RA1; Fig. 1D ) was unaltered in cultured myotubes derived from people with NGT vs. T2DM, suggesting posttranscriptional regulation of IL-13 production. Expression of the differentiation markers desmin and myogenin was unaltered between cultured myotubes derived from people with NGT vs. T2DM (Table 2) .
Interestingly, fasting serum IL-13 levels were reduced by 45% in subjects with T2DM ( Fig. 1E ; also see Table 1 for subject characteristics). To elucidate factors regulating serum IL-13 levels, a stepwise regression analysis with weight, BMI, fasting plasma glucose, Hb A 1c , insulin, triglycerides, and C-peptide as independent factors was performed. In this model, insulin remained as a significant independent predictor of serum IL-13 levels ( Fig. 1F and Table 3) .
IL-13 selectively enhances glucose metabolism in cultured myotubes. To explore whether IL-13 alters glucose or lipid metabolism, the metabolic effects of acute IL-13 exposure was determined in cultured human myotubes. IL-13 was without effect on fatty acid oxidation ( Fig. 2A) . Conversely, IL-13 exposure increased basal glucose uptake in cultured myotubes from NGT subjects 16%. However, IL-13 exposure did not significantly increase basal glucose uptake in muscle cells from T2DM subjects (Fig. 2B) . IL-13 exposure significantly increased glucose incorporation to glycogen in skeletal muscle cells from NGT and T2DM subjects by 28 and 31%, respectively (Fig. 2C) . Similar results were noted following exposure to IL-4 (data not shown). To explore whether IL-13 directly alters basal glucose metabolism, myotubes were cultured in the presence of an IL-13-neutralizing antibody. Basal glycogen synthesis was reduced by 11% following IL-13 neutralization (Fig. 2D) . IL-13 increased glucose oxidation in skeletal muscle cells from NGT and T2DM subjects 23 and 28%, respectively (Fig. 2E) . Thus, IL-13 not only increases glucose transport but also enhances subsequent steps in glucose metabolism. In contrast, IL-13 decreased lactate production, an indicatior of nonoxidative utilization of pyruvate, in myotubes derived from NGT and T2DM subjects by 40 (P Ͻ 0.01) and 35% (P Ͻ 0.1), respectively (Fig. 2F) . To elucidate the metabolic action of IL-13 on other insulin-sensitive tissues, glucose uptake and lipolysis were determined in adipocytes. In contrast to human skeletal muscle, IL-13 was without effect on either glucose uptake or lipolysis in isolated human adipocytes (data not shown). Furthermore, IL-13 was without effect on glucose uptake in mouse 3T3-L1 adipose cells (data not shown).
IL-13 activates canonical insulin-signaling cascades involving phosphatidylinositol 3-kinase.
The effect of IL-13 on the insulin-signaling pathway in cultured human skeletal muscle cells was determined by assessing Akt and GSK-3 phosphorylation. Exposure of cultured human skeletal muscle cells to IL-13 resulted in the expected and dose-dependent increased phosphorylation of STAT6, a key signal transducer of IL-13 activity (Fig. 3, A and B) . Consistent with previous reports in other cell types of human origin (30, 42, 46) , IL-13 increased Akt phosphorylation, albeit to a lesser extent than that observed for insulin stimulation (Fig. 3, A and C) . Insulin, but not Results are means Ϯ SE (n ϭ 6). miRNA, microRNA. Expression of mRNA and miRNA in differentiated skeletal muscle cultures from NGT or T2DM subjects. IL-13, increased phosphorylation of GSK-3␣ (Fig. 3, A and D) . The phosphatidylinositol (PI) 3-kinase inhibitor Wortmannin blocked insulin as well as IL-13-dependent phosphorylation of Akt and GSK-3, but it did not affect IL-13-dependent STAT6 phosphorylation. No additive effects were noted on phosphorylation of Akt and GSK-3 when muscle cells were exposed to insulin and IL-13 at the same time. Wortmannin also blocked the IL-13-dependent increase in glucose incorporation to glycogen (Fig. 3E) . Taken together, these results suggest IL-13 has an "insulin-like" effect on glucose metabolism in human skeletal muscle cells.
IL-13 secretion is regulated by miRNA let-7.
Since IL-13 production from myotubes derived from people with T2DM was reduced without changes in mRNA levels, we hypothesized that a mechanism of posttranscriptional regulation by miRNAs may play a role. To test this hypothesis, we analyzed the human IL-13 sequence for candidate miRNAs predicted to target the gene 3=-untranslated region (UTR) (13, 25) . Candidate miRNAs included members of the let-7 family. Expression level of miRNA let-7a (P Ͻ 0.05) and let-7d (P Ͻ 0.1) was increased in cultured myotubes from T2DM patients by 69 and 43%, respectively, vs. NGT subjects (Fig. 4A) . All let-7 family members contained identical seed regions that were responsible for the inhibitory effect on their targets, including IL-13 (Fig. 4B) . Expression of other members of the let-7 family, including let-7b, -c, -d, -f, and -i, as well as miR-98, which displays a similar seed region, did not differ in skeletal muscle cultures established from NGT vs. T2DM patients (Table 2 ). To explore whether increased expression of miRNA let-7 provides a molecular mechanism for the reduction in IL-13, skeletal muscle cells were transfected with a let-7a or let-7d mimic, resulting in a Ͼ50% reduction in IL-13 secretion (Fig. 4C) . The let-7-mediated reduction in IL-13 secretion was independent of a change in mRNA expression level of IL-13 or IL-13RA1 (data not shown), consistent with our finding of similar mRNA levels of these genes between cultures derived from NGT or T2DM participants. Let-7 targets multiple components of the insulin/PI3K pathway, including insulin receptor, insulin-like growth factor receptor, and insulin receptor substrate 2 (47). However, mRNA expression of these signaling components was unaltered in human muscle cells after targeted overexpression of let-7a (Fig. 4D) or between muscle cells derived from people with NGT or T2DM (Fig. 4E) . Finally, we determined serum IL-13 levels and skeletal muscle let-7a or let-7d expression in eight healthy young volunteers and noted a negative correlation (r ϭ Ϫ0.79, P Ͻ 0.05; r ϭ Ϫ0.84, P Ͻ 0.05, respectively), suggesting that elevated skeletal muscle let-7 content may reduce serum IL-13 (Fig. 4, F 
and G).

DISCUSSION
Here, provide evidence that cultured muscle from older, overweight subjects with T2D have a reduced secretion of IL-13, and we propose a role for IL-13 on skeletal muscle glucose metabolism. In cultured myotubes established from T2DM patients, the IL-13 secretion was reduced in parallel with increased expression of miRNA let-7a. Overexpression of either miRNA let-7a or let-7d in cultured myotubes, direct translational repressors of the human IL-13 gene, reduced IL-13 secretion without altering IL-13 mRNA expression. Furthermore, a neutralizing antibody against IL-13 decreased basal glycogen synthesis, suggesting that IL-13 acts as a myokine that promotes glucose metabolism in skeletal muscle. Finally, in vivo, insulin was a significant independent predictor of serum IL-13 levels, and serum IL-13 was negatively correlated with skeletal muscle expression of let-7a and let-7d.
T2DM and obesity are often associated with a chronic, low-grade, inflammatory state in adipose tissue (44) . Proinflammatory cytokines such as TNF␣, IL-6, and IL-1␤ attenuate insulin action in adipocytes (18, 19) and reduce whole body insulin sensitivity. Proinflammatory cytokines also act directly B: glucose uptake (n ϭ 8 -9). C: glycogen synthesis (n ϭ 7-8). D: glycogen synthesis (n ϭ 4) after the addition of a neutralizing IL-13 antibody (0.13 g/ml) to the media. E: glucose oxidation (n ϭ 6). F: induction of lactate production (n ϭ 6). IL-13 concentration was 1 ng/ml and insulin 120 nM unless otherwise indicated in figure. Results are means Ϯ SE. *P Ͻ 0.05, **P Ͻ 0.01, and ***P Ͻ 0.001 relative to basal. DPM, disintegrations/min. on skeletal muscle to attenuate insulin signaling and glucose metabolism (4) . Communication between adipose tissue and skeletal muscle to tightly control metabolic homeostasis involves adipose tissue-derived cytokines or "adipokines" (18) . Skeletal muscle acts as an endocrine organ that secretes myokines and various peptides that have autocrine metabolic actions in addition to effects on peripheral tissues (34) . Since skeletal muscle is by mass the largest organ in the body, modest changes in myokine secretion may contribute to the regulation of whole body metabolism. The dysregulation of IL-13 secretion in T2DM may compromise skeletal muscle glucose metabolism in an autocrine and/or endocrine fashion. Despite the fact that we noted a negative correlation between skeletal muscle expression of let-7a and let-7d and serum IL-13, the source of IL-13 in serum samples is likely to originate from several tissues and will require further investigation. In contrast, cultured human muscle represents 97-99% myogenic cells, and thus the IL-13 in the media is likely to originate from myogenic cells. IL-13 has been shown to play a role in muscle regeneration but to be without effect on satellite cell proliferation (17) . In line with this, no differences in differentiation markers were observed between cultures from T2DM or NGT subjects.
In contrast to results noted in skeletal muscle cells, IL-13 does not alter glucose or lipid metabolism in adipose cells. Although IL-13 may not directly modulate metabolism in adipose cells, reduced IL-13 activity may exacerbate adipose insulin sensitivity. In obesity, activated macrophages infiltrate the adipose tissue and secrete proinflammatory cytokines that further impair insulin signaling (3, 43) . Although IL-13 was without direct metabolic impact on human adipocytes, in mice IL-13 has a suppressive effect on M1 macrophage activity, and therefore, the reduced IL-13 levels may promote the release of proinflammatory cytokines (33) . For example, following a high-fat diet, STAT6-knockout mice, which have defective IL-13 signaling, have profound insulin resistance and reduced anti-inflammatory M2 macrophages (32) . Here, we report that IL-13 enhanced basal glucose incorporation into glycogen and glucose oxidation to a similar extent in cultured myotubes derived from people with NGT or T2DM, indicating that in T2DM IL-13 production or secretion is impaired, whereas aspects of IL-13 signal transduction and metabolic action are maintained. Since obesity is strongly linked to T2DM, adipose cells could constitute an important source of IL-13. However, in contrast to mouse 3T3-L1 adipocytes (22) Basal Insulin 12nM +IL13 10ng/ml IL13 1ng/ml IL13 10ng/ml Insulin 12nM (23). IL-4 displayed similar potency as IL-13 to induce glycogen synthesis in myotubes. Thus, we cannot exclude the possibility that, in T2DM patients, any reduction in glucose metabolism due to decreased serum IL-13 levels could be mediated partly by disturbances in IL-4 secretion. However, serum IL-4 levels were below detection limits, whereas mRNA expression of IL-4 and its receptor (IL-4R) was unaltered between people with NGT or T2DM (data not shown), providing evidence against a role for IL-4. Skeletal muscle cells derived from T2DM subjects maintain insulin resistance in vitro (21) , but under some conditions, this is not always noted (15) . For example, insulin resistance is observed at the level of glycogen synthesis but not glucose transport in cells derived from T2DM patients. In this study, we did not observe insulin resistance in the cultured skeletal muscle cells from T2D patients with respect to glucose metabolism; however, despite this, the myotubes derived from T2DM patients are less responsive to IL-13 stimulation than cells derived from NGT subjects. IL-13 increased glucose uptake and conversion into glycogen, glucose oxidation, and suppression of lactate production in cells derived from people with NGT. However, in myotubes derived from T2DM patients, IL-13-induced metabolic responses were impaired, with only a significant effects on glycogen synthesis and glucose oxidation noted. We have previously noted impaired metabolic responses to endothelin 1 (40) and IL-6 (21) in cells from derived T2DM patients, which may be indicative of a general metabolic impairment that persists in these cells.
miRNAs are implicated in regulation of gene expression and several muscle-specific processes (2, 8, 9, 28 ) and the control of metabolism in T2DM (37) . miRNAs can reduce cellular protein levels either by inhibiting translation or through mRNA degradation (5) . The reduced myotube secretion of IL-13 into the culture media was coupled to an increased expression of miRNA let-7. Members of the let-7 family have a direct inhibitory effect on IL-13 in coexpression studies (24, 36) . In addition, let-7 inhibits protein expression at the translational level (31, 35) . Here, we provide evidence that IL-13 secretion is reduced in skeletal muscle cells transfected with a let-7a or let-7d mimic. Furthermore, reducing the media IL-13 level using a neutralizing IL-13 antibody decreased basal glycogen synthesis, further indicating that downregulation of IL-13 attenuates glucose metabolism. Hence, reduced media IL-13 levels and increased miRNA let-7a expression in skeletal muscle cells from T2DM patients supports a novel role for let-7 in the regulation of IL-13 secretion and action on glucose metabolism in skeletal muscle. Notably, the let-7d-mediated decrease in myotube IL-13 secretion occurred in the absence of any changes in IL-13 mRNA expression.
Administration of a specific anti-let-7 compound to obese mice improves glucose homeostasis and insulin sensitivity, primarily by targeting let-7 in muscle and liver (14) . Overexpression of let-7 in mouse skeletal muscle is associated with insulin resistance and impaired glucose tolerance (47) . This overexpression of let-7 was associated with a let-7-mediated repression of components of the insulin/PI3K/mammalian target of rapamycin pathway, including abundance of the insulinlike growth factor receptor, the insulin receptor, and insulin receptor substrate-2 (47). Interestingly, insulin-stimulated Akt phosphorylation was not reduced in myotubes from T2DM patients, indicating that the function of the insulin-PI3K axis is preserved (40) . This could be due to the more modest endogenous overexpression of let-7 in muscle from T2DM subjects (ϳ50%) compared with transgenic overexpression (6-to 10-fold) (47) . Mice lacking IL-13 are hyperglycemic and hyperinsulinemic and have reduced insulin-mediated suppression of hepatic glucose production as well as impaired glucose uptake into skeletal muscle and white adipose tissue (41) . The latter finding may implicate adipose tissue as an IL-13-sensitive organ. However, cultured human adipocytes are unresponsive to IL-13 exposure. Thus the insulin resistance in white adipose tissue from IL-13-deficient mice is likely a secondary phenomenon arising from impairments in liver or skeletal muscle. Nevertheless, this animal model further underscores the notion that the reduction in both circulating IL-13 levels and skeletal muscle IL-13 secretion, as noted here in T2DM patients, is of physiological relevance with respect to impaired glucose metabolism. Thus in conclusion, serum level of IL-13 is reduced in T2DM patients. IL-13 is synthesized and released by skeletal muscle through a mechanism involving let-7, and this effect is attenuated in insulin-resistant T2DM patients. Thus our data indicate that IL-13 is a myokine that plays an autocrine role on glucose uptake and metabolism in metabolic disease. Whether IL-13 has similar actions in other metabolically active organs in humans, such as liver and heart, remains to be established. 
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